NDC 63713-0461-02: thrombin human 2000 [iU]/2mL Powder, For Solution, 2 mL Vial
This is a package of 2 mL of thrombin human 2000 [iU]/2mL Powder, For Solution from Ethicon, Inc, first listed with the FDA Sep 2009 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 63713-461-02 alone.
- Record
- FDA NDC Directory package listing · Plasma derivative
- Code segments
- 63713 labeler · 461 product · 02 package
- Package marketed since
- Sep 19, 2009
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 6371346102 6
- FDA record last changed
- Nov 12, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 748321
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Blood Coagulation Factor class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 63713-0461-02 You're viewing this Main listing | 2 mL in 1 VIAL, GLASS | 2009-09-19 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| thrombin human 2000 [iU]/2mLthis 63713-0461-02 | Ethicon, | 2 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII ZIF514RVZR
A protein derived from human blood plasma. In medicines, it acts as a stabilizer and binder, helping maintain drug potency and form, and may improve how the medication disperses or dissolves in the body.
-
UNII M4I0D6VV5M
Calcium chloride is a salt compound that acts as a firming agent and source of calcium ions in medications. It's used in formulations to help maintain tablet structure, improve texture, or serve as a buffering agent.
-
UNII 3OWL53L36A
A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
-
UNII 4550K0SC9B
Sodium acetate is a salt derived from acetic acid. It acts as a buffer to help maintain the medicine's pH stability and may serve as a preservative or solubilizer in liquid formulations.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Ethicon, Inc labeler code 63713
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE EVITHROM™ Thrombin, Topical (Human), is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. EVITHROM™ Thrombin, Topical (Human), may be used in conjunction with an Absorbable Gelatin Sponge, USP. EVITHROM™ is a topical thrombin indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical ( 1 ).
EVITHROM™ may be used in conjunction with an Absorbable Gelatin Sponge, USP ( 1 ).
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For topical use only. DO NOT INJECT ( 2.2 ). Apply EVITHROM™ on the surface of bleeding tissue only. The amount of EVITHROM™ required depends upon the area of tissue to be treated and the method of application. In clinical studies, volumes up to 10 ml were used in conjunction with Absorbable Gelatin Sponge, USP ( 2.2 ).
2.1Dose For Topical Use Only. DO NOT INJECT. The amount of EVITHROM™ required depends upon the area of tissue to be treated and the method of application. As an approximate guide, volumes up to 10 ml were used in clinical studies where EVITHROM™ was used in conjunction with Absorbable Gelatin Sponge, USP.
2.2Preparation Use aseptic technique when handling vials and syringes. Remove the flip-off plastic cap from the vial to expose the rubber stopper. Reconstitute the lyophilized human thrombin powder with 2 ml of sterile Water for Injection, USP using the provided reconstitution device. Shake gently until the solution is clear. Reconstituted solution is stable for up to 8 hours at room temperature and should be used within this time period.
2.3Application Techniques Apply only on the surface of bleeding tissue. EVITHROM™ Use alone Sponge target surface (do not wipe) or suction free of blood before application. Flood the surface with EVITHROM™ using a sterile syringe and small gauge needle.
Avoid sponging after treatment, to ensure that the clot remains securely in place. EVITHROM™ in conjunction with Absorbable Gelatin Sponge, USP Prepare the desired shape of the Absorbable Gelatin Sponge, USP. (see Absorbable Gelatin Sponge, USP circular for additional instructions for use).
Transfer EVITHROM™ into a sterile container using aseptic techniques. Immerse gelatin sponge into the EVITHROM™ solution. Vigorously knead the sponge with moistened gloved fingers until all air is expelled and it can return to its original size and shape.
Hold the saturated sponge in place with gauze or cotton pledget using moderate pressure until hemostasis is achieved.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS EVITHROM™ is a sterile lyophilized powder for solution 2000 (1600-2400) units of lyophilized human thrombin powder for reconstitution. After reconstituted, the final solution contains 1000 (800-1200) units/ml of human thrombin. Potency, expressed in units, is determined using a clotting assay against an internal reference standard for potency that has been calibrated against the World Health Organisation (WHO) Second International Standard for Thrombin, 01/580.
Therefore, a unit used herein is equivalent to an International Unit. EVITHROM™ is a lyophilized powder for solution containing 2000 (1600-2400) units of human thrombin. After reconstituted the final solution contains 1000 (800-1200) units/ml of EVITHROM™ ( 3 ).
⛔ Contraindications ▾
4 CONTRAINDICATIONS Do not use in individuals known to have an anaphylactic or severe systemic reaction to EVITHROM™ or to human blood products. Do not use for the treatment of severe or brisk arterial bleeding. Do not use in individuals known to have an anaphylactic or severe systemic reaction to EVITHROM™ or to human blood products ( 4 ) . Do not use for treatment of severe or brisk arterial bleeding ( 4 ) .
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Potential risk of thrombosis if absorbed systemically ( 5.1 ) . May carry a risk of transmitting infectious agents such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite manufacturing steps designed to reduce the risk of viral transmission ( 5.2 ) . Hypersensitivity reactions, including anaphylaxis, may occur ( 5.1 ) .
5.1Thrombosis There is a risk of thrombosis if absorbed systemically. Apply topically only.
5.2Anaphylactic/Hypersensitivity Reactions Anaphylactic reactions may occur in rare cases. No adverse events of this type were reported during the conduct of the clinical trials. Severe hypotensive reactions require immediate intervention using current principles of shock therapy.
5.3Transmission of Infectious Agents Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of transmitting an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections and by inactivating and removing certain viruses. Despite these measures, such products can still potentially transmit disease.
There is also the possibility that unknown infectious agents may be present in such products.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most common adverse reactions during clinical trial (reported in at least 2% of subjects treated with EVITHROM™) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count. The most common adverse reactions (incidence 2%) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count ( 6 ). None of the patients treated with EVITHROM™ developed antibodies to human thrombin or to human Factor V/Va.
The clinical significance of these findings is unknown ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact ETHICON Customer Support Center at (877) 384-4266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In a multicenter, prospective, controlled, randomized, double-blinded clinical trial of 305 subjects where EVITHROM™ (n=153) was compared with bovine thrombin (n=152), occurrence of adverse events was not statistically different between the two groups.
Overall, adverse events occurred in similar proportions of subjects in the two groups (see Table 1 ). No clinically significant differences were seen in age (<65 years, >65 years) or gender subgroup analyses of adverse events. At least one serious adverse event (SAE) was reported for 26/153 (17%) subjects treated with human thrombin and 17/152 (11%) subjects treated with bovine thrombin.
The SAEs reported were associated with post-surgical complications (e.g. wound infection 3/153 for EVITHROM™ and 2/152 for bovine thrombin) and the medical condition of the subject and were not considered related to study drug. Two subjects (1.3%) in EVITHROM™ group experienced a treatment emergent severe adverse event: respiratory arrest and post-procedural hematoma (in one subject) and extradural hematoma. Three subjects in the bovine thrombin group experienced a treatment emergent severe adverse event: hyperhidrosis, pyrexia and post-procedural hematoma.
No deaths were reported during the study period. Viral serology was not monitored during the trial with EVITHROM™. However, no adverse events indicative of infection with transfusion-transmissible agents were reported.
Table 1: Incidence of subjects with related adverse events reported in at least 2% of subjects treated with either human or bovine thrombin Thrombin Type System Organ Class/Adverse Event EVITHROM™ (n=153) Bovine (n=152) Total (n=305) Investigations 11 (7.2%) 14 (9.2%) 25 (8.2%) Activated partial thromboplastin time increased 4 (2.6%) 8 (5.3%) 12 (3.9%) International normalized ratio increased 4 (2.6%) 5 (3.3%) 9 (3.0%) Lymphocyte count decreased 4 (2.6%) 2 (1.3%) 6 (2.0%) Prothrombin time prolonged 4 (2.6%) 8 (5.3%) 12 (3.9%) Neutrophil count increased 3 (2.0%) 2 (1.3%) 5 (1.6%) Skin and Subcutaneous Tissue Disorders 1 (0.7%) 3 (2.0%) 4 (1.3%) Pruritus 1 (0.7%) 3 (2.0%) 4 (1.3%) General Disorders and Administration Site Conditions 0 3 (2.0%) 3 (1.0%) Immunogenicity In the clinical study, serum samples were collected at baseline and at 5 weeks post-surgery for evaluation of antibodies to bovine thrombin, bovine Factor V/Va, human thrombin, and human Factor V/Va.
Samples were collected at both time points for 81.3% of the subjects. The ELISA data were adjudicated by a panel of experts blinded to treatment assignment. After reviewing all data, the panel used an algorithm for assigning outcomes for each antigen: seroconversion negative or seroconversion positive.
The protocol did not specify any comparative analysis for immunogenicity data, only descriptive statistics. The adjudicated results show that 3.3% of the subjec… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Animal Reproduction studies have not been conducted with EVITHROM™. EVITHROM™ should only be used in pregnancy if clearly indicated ( 8.1 ).
8.1Pregnancy Risk Summary There are no data with EVITHROM™ use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with EVITHROM™. It is not known whether EVITHROM™ can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
EVITHROM™ should be given to a pregnant woman only if clearly needed. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
8.2Lactation Risk Summary There is no information regarding the presence of EVITHROM™ in human milk, the effect on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EVITHROM™ and any potential adverse effects on the breastfed infant from EVITHROM™ or from the underlying maternal condition.
8.4Pediatric Use Of the 155 patients undergoing liver surgery who were treated in adequate and well-controlled studies of EVICEL™ Fibrin Sealant (Human), in which EVITHROM™ is a component, eight were pediatric patients. Of these, five were less than 2 years old and three were between 2 and 12 years old. Use of EVITHROM™ in pediatric patients is supported by these data and by extrapolation of findings for safety and efficacy in adults.
8.5Geriatric Use Sixty three (63) subjects over 65 years of age received EVITHROM™ in the clinical trial. No differences in safety or effectiveness were observed between the elderly and younger patients. Greater susceptibility of older patients to adverse reactions cannot be ruled out.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no data with EVITHROM™ use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with EVITHROM™. It is not known whether EVITHROM™ can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
EVITHROM™ should be given to a pregnant woman only if clearly needed. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
🧒 Pediatric Use ▾
8.4Pediatric Use Of the 155 patients undergoing liver surgery who were treated in adequate and well-controlled studies of EVICEL™ Fibrin Sealant (Human), in which EVITHROM™ is a component, eight were pediatric patients. Of these, five were less than 2 years old and three were between 2 and 12 years old. Use of EVITHROM™ in pediatric patients is supported by these data and by extrapolation of findings for safety and efficacy in adults.
🧓 Geriatric Use ▾
8.5Geriatric Use Sixty three (63) subjects over 65 years of age received EVITHROM™ in the clinical trial. No differences in safety or effectiveness were observed between the elderly and younger patients. Greater susceptibility of older patients to adverse reactions cannot be ruled out.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY EVITHROM™ requires no intermediate physiological agent because it clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself. The speed with which thrombin clots blood is dependent upon the concentration of both thrombin and fibrinogen.
12.1Mechanism of Action Thrombin (coagulation Factor IIa) is a highly specific protease that transforms plasma fibrinogen into fibrin which, in the presence of Factor XIII in the patient's plasma, is cross-linked to form a stable clot. When applied to a surgical wound where bleeding is present, thrombin activates fibrinogen in the patient's plasma to form fibrin, which results in clot formation and hemostasis. The fibrin clot is stabilized by cross-linking occurring as a result of activation of the patient's endogenous Factor XIII, which requires the presence of calcium.
🧬 Mechanism of Action ▾
12.1Mechanism of Action Thrombin (coagulation Factor IIa) is a highly specific protease that transforms plasma fibrinogen into fibrin which, in the presence of Factor XIII in the patient's plasma, is cross-linked to form a stable clot. When applied to a surgical wound where bleeding is present, thrombin activates fibrinogen in the patient's plasma to form fibrin, which results in clot formation and hemostasis. The fibrin clot is stabilized by cross-linking occurring as a result of activation of the patient's endogenous Factor XIII, which requires the presence of calcium.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING EVITHROM™ is supplied in a single-use 2 ml vial containing 2000 (1600-2400) units of lyophilized human thrombin powder for reconstitution in 2 ml Water for Injection, USP. NDC 63713-461-02 Store EVITHROM™ powder vials at 2- 25°C (36-77°F) for up to 2 years. Discard if the packaging of EVITHROM™ is damaged.
Keep the vials protected from light. Store reconstituted EVITHROM™ solution at room temperature for up to 8 hours. Do not freeze or refrigerate EVITHROM™ once it has been reconstituted.
Discard unused contents.
📦 Storage and Handling ▾
Store EVITHROM™ powder vials at 2- 25°C (36-77°F) for up to 2 years. Discard if the packaging of EVITHROM™ is damaged. Keep the vials protected from light. Store reconstituted EVITHROM™ solution at room temperature for up to 8 hours. Do not freeze or refrigerate EVITHROM™ once it has been reconstituted. Discard unused contents.
📋 Description ▾
11 DESCRIPTION EVITHROM™ is a sterile lyophilized powder of purified human thrombin (1600-2400 units) of white to slightly yellowish color. When reconstituted, EVITHROM™ solution, pH 6.8-7.2, is clear to slightly opalescent and colorless to slightly yellowish. Other inactive ingredients are Calcium chloride, Human albumin, Mannitol, Sodium acetate EVITHROM™ is made from pooled Human Source obtained from US licensed plasma collection centers.
Individual plasma units obtained for production of EVITHROM™ are tested by licensed serological tests for HBsAg, HIV 1 & 2 Ab and HCV Ab. Additionally, the plasma units are tested by licensed Nucleic Acid Testing (NAT) for HIV-1, HCV, HBV, HAV and parvovirus B19. All tests for HIV, HCV, HBV and HAV must be negative (non-reactive).
However, since the effectiveness of the HBV and HAV NAT methods in detecting low levels of viral material is still under investigation, the significance of a negative result for these viruses is unknown. The level of parvovirus B19 contamination is not permitted to exceed 10,000 copies/ml. This limit is applied to restrict the viral load of parvovirus B19 in the starting plasma pool.
In addition to the screening of plasma units, each manufacturing pool is tested for HBsAg, HIV-1 & 2 Ab, HCV NAT and for parvovirus B19 by NAT. Manufacturing pool testing, however, is of lower sensitivity than individual unit testing. EVITHROM™ is manufactured by purification of prothrombin from cryo-poor plasma followed by activation with calcium chloride, or alternatively with calcium chloride in combination with Gluconate.
The manufacturing process includes two targeted steps for inactivation or removal of viruses. The first of these is treatment with a solvent/detergent (S/D) mixture (1% tri-n-butyl phosphate and 1% Triton X-100 or 1% Polysorbate-80 and 0.3% tri-n-butyl phosphate) for 6 hours at 26°C to inactivate lipid enveloped viruses. The S/D reagents are removed by cation exchange chromatography.
Mannitol and human albumin are used to stabilize the solution, which undergoes nanofiltration for removal of both enveloped and non-enveloped viruses. After nanofiltration, the solution is formulated with calcium chloride, sterile filtered and aseptically filled and frozen. The effectiveness of the S/D treatment and nanofiltration procedures for reducing virus content has been assessed using a series of viruses with a range of physico-chemical characteristics.
The results of the validation studies are summarized in Table 2. Table 2: Reducing factors of S/D treatment and nanofiltration for a series of viruses Virus HIV-1 BVDV PRV EMCV HAV MVM PPV Reduction factor (log 10 ) HIV-1: Human Immunodeficiency Virus Type 1; BVDV: Bovine Viral Diarrhea Virus; PRV: Pseudorabies Virus; EMCV: Encephalomyocarditis Virus; HAV: Hepatitis A Virus; MVM: Minute Virus of Mouse; PPV: Porcine Parvovirus SD Treatment ≥5.5 >4.6 >4.2 Not Done Not Done Not Done Not Done Nanofiltration ≥4.6 ≥5.6 ≥5.7 ≥7.4 ≥7.5 ≥6.3 ≥
5.6Global Reduction Factor ≥10.1 ≥10.2 ≥9.9 ≥7.4 ≥7.5 ≥6.3 ≥5.6
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Inform patients of the following: Some viruses such as hepatitis A virus and parvovirus B19 are particularly difficult to remove or inactivate. Parvovirus B19 most seriously affects pregnant women or immune-compromised individuals. Symptoms of parvovirus B19 infection include: fever, drowsiness, chills and runny nose followed about two weeks later by a rash and joint pain.
Evidence of hepatitis A may include several days to weeks of poor appetite, fatigue and low-grade fever followed by nausea, vomiting and abdominal pain. Dark urine and a yellowed complexion are also common symptoms. Consult your physician if such symptoms appear.
If absorbed systemically EVITHROM™ could potentially cause blood clotting disorders. Consult your physician if leg tenderness or swelling, chest pain, or shortness of breath appears.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES EVITHROM™ was compared with bovine thrombin in a multicenter, prospective, randomized, controlled, double-blinded clinical trial of 305 subjects at 22 centers in the US. Subjects undergoing elective cardiovascular, neurologic (spinal) or general surgical procedures were randomized (stratified by surgical specialty) when there was oozing or bleeding of mild intensity that could not be controlled by other surgical techniques and the surgeon determined that a topical hemostatic agent was necessary. Bovine thrombin and EVITHROM™ were applied with SURGIFOAM™ Absorbable Gelatin Sponge, USP.
Treatment with EVITHROM™ was comparable to treatment with bovine thrombin in achieving hemostasis within: 10 minutes of product application and 6 and 3 minutes of product application. Table 3: Efficacy for Intent to Treat (ITT) population Time Interval Treatment Group: # Successes/N (%) Ratio Human/Bovine 95% CI for Ratio Human/Bovine 95% CI is for the ratio of proportions of success , For the two treatments to be equivalent, both limits of the confidence interval must have been within (0.80, 1.25) EVITHROM™ N=153 Bovine thrombin N=152 10 minutes 149/153 (97.4) 148/152 (97.4) 1.00 0.96, 1.05 6 minutes 145/153 (94.8) 141/152 (92.8) 1.02 0.96, 1.09 3 minutes 112/153 (73.2) 110/152 (72.4) 1.01 0.88,
1.16Table 4: Efficacy at 6 minutes (ITT population) Surgical Specialty Treatment Group: # Successes/N (%) Ratio Human/Bovine 95% CI for Ratio Human/Bovine 95% CI is for the ratio of proportions of success , For the two treatments to be equivalent, both limits of the confidence interval must have been within (0.80, 1.25) EVITHROM™ Bovine thrombin Cardiovascular 44/47 (93.6) 38/46 (82.6) 1.13 0.97,
1.36Neurosurgical (Spine) 60/61 (98.4) 59/60 (98.3) 1.00 0.93,
1.08General Surgery 41/45 (91.1) 44/46 (95.7) 0.95 0.82,
1.08Overall 145/153 (94.8) 141/152 (92.8) 1.02 0.96,
1.09At the 6 minute and 10 minute time points, >90% of subjects from all surgeries in both study groups had achieved hemostasis. The following results were documented for the 3 minute time point as stratified by surgery and study treatment: (1) cardiovascular surgery - human thrombin: 61.7%; bovine thrombin: 63.0%, (2) spinal surgery - human thrombin: 83.6%; bovine thrombin: 80.0%, (3) general surgery - human thrombin: 71.1%; bovine thrombin: 71.7% for an overall ratio of proportions of 1.01.
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of EVITHROM™ due to the human origin of thrombin. Studies were performed in bacteria to determine mutagenicity of human thrombin alone, and solvent/detergent residues [tri-n-butyl phosphate (TnBP) and Triton X-100], used in the virus inactivation manufacturing step. These studies were negative for both thrombin and for TnBP or Triton X-100 at all concentrations tested.
All concentrations of the combination of TnBP and Triton X-100 also tested negative in assays performed to determine mammalian cell mutagenicity, chromosomal aberrations and micronuclei induction. No study was performed for Polysorbate-80 and tri-n-butyl phosphate. The effect of EVITHROM™ on fertility has not been evaluated.
Reproductive studies were performed in rats with the combination of solvent detergent impurities, TnBP and Triton X-100 at doses up to approximately 600-fold human dose of TnBP (900 µg/kg/day) and 3000-fold human dose of Triton X-100 (4500 µg/kg/day) resulted in increased post-implantation loss and an increased number of late resorptions. Other studies performed with combinations of TnBP (300-fold human dose, 450 µg/kg/day) and Triton X-100 (1500-fold human dose, 2250 µg/kg/day) resulted in increased resorption rates, decreased fetal body weights, and an increased number of runts.
No embryo-fetal adverse effects were observed at doses up to 300 µg/kg/day TnBP and 1500 µg/kg/day Triton X-100, 200-fold and 1000-fold the human dose, respectively.
13.2Animal Toxicology and/or Pharmacology EVICEL Fibrin Sealant (Human), which includes EVITHROM™ as one of the active components, was classified as non-irritant in the Primary Cutaneous Irritation Test and slightly irritant in the Ocular Irritation test. Neurotoxicity studies performed with EVITHROM™ or with EVICEL confirmed that intracerebral application of thrombin was not associated with any evidence of neurotoxicity. No toxicological effects due to solvent/detergent reagents [tri-n-butyl phosphate (TnBP) and Triton X-100] used in the virus inactivation procedure are expected since the residual levels are less than 5 µg/ml.
This evaluation was not performed for Polysorbate-80.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of EVITHROM™ due to the human origin of thrombin. Studies were performed in bacteria to determine mutagenicity of human thrombin alone, and solvent/detergent residues [tri-n-butyl phosphate (TnBP) and Triton X-100], used in the virus inactivation manufacturing step. These studies were negative for both thrombin and for TnBP or Triton X-100 at all concentrations tested.
All concentrations of the combination of TnBP and Triton X-100 also tested negative in assays performed to determine mammalian cell mutagenicity, chromosomal aberrations and micronuclei induction. No study was performed for Polysorbate-80 and tri-n-butyl phosphate. The effect of EVITHROM™ on fertility has not been evaluated.
Reproductive studies were performed in rats with the combination of solvent detergent impurities, TnBP and Triton X-100 at doses up to approximately 600-fold human dose of TnBP (900 µg/kg/day) and 3000-fold human dose of Triton X-100 (4500 µg/kg/day) resulted in increased post-implantation loss and an increased number of late resorptions. Other studies performed with combinations of TnBP (300-fold human dose, 450 µg/kg/day) and Triton X-100 (1500-fold human dose, 2250 µg/kg/day) resulted in increased resorption rates, decreased fetal body weights, and an increased number of runts.
No embryo-fetal adverse effects were observed at doses up to 300 µg/kg/day TnBP and 1500 µg/kg/day Triton X-100, 200-fold and 1000-fold the human dose, respectively.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 2 ml Vial Label - Grifols THROMBIN TOPICAL (HUMAN) EVITHROM ™ Lyophilized Powder NDC-63713-461-02 This bottle contains 2000 (1600-2400) units of lyophilized powder of Thrombin (human), calcium chloride, albumin (human), mannitol and sodium acetate. Store unopened vial at 2-25°C. Reconstitute in 2ml of Water for Injection, USP to obtain 1000 (800-1200) units/ml.
Do not freeze or refrigerate once reconstituted. Vials are for single use only. Discard unused contents.
Protect from light. See enclosed instructions. Evithrom 2000
PRINCIPAL DISPLAY PANEL - 2 ml Vial Label - Patheon THROMBIN TOPICAL (HUMAN) EVITHROM ™ Lyophilized Powder NDC-63713-461-02 This bottle contains 2000 (1600-2400) units of lyophilized powder of Thrombin (human), calcium chloride, albumin (human), mannitol and sodium acetate. Store unopened vial at 2-25°C. Reconstitute in 2ml of Water for Injection, USP to obtain 1000 (800-1200) units/ml.
Do not freeze or refrigerate once reconstituted. Vials are for single use only. Discard unused contents.
Protect from light. See enclosed instructions. PRINCIPAL DISPLAY PANEL - 2 ml Vial Label - Patheon
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |